Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping ...

On Friday, February 7, a hearing took place in the Montana state legislature on a bill that would ban the use of mRNA ...

The study, published by the McCullough Foundation, says the deaths reported in VAERS are estimated to be underreported by a ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Russian mRNA cancer 'vaccine' shows promise in pre-clinical trials, part of growing immunotherapy trend in cancer treatment.

A research team from POSTECH has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

In principle, mRNA vaccines are ideal for health emergencies as they can be quickly mass produced using a template. The problem is that current cell-based template production methods take too long, ...

The company's financials are heavily reliant on COVID-19 vaccines, with declining demand impacting revenue and profitability. BioNTech's strong balance sheet and innovative mRNA technology show ...